Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus Published
A Study of Nasal Glucagon (LY900018) in Japanese Participants With
Summary
This study compared the efficacy and safety of nasal glucagon versus intramuscular glucagon for treating insulin-induced hypoglycemia, targeting diabetic patients in Japan. Detailed clinical trial information was published via the FEvIR platform.
Details
The study, titled 'A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus,' is a Phase 3 trial designed to compare treatment options for hypoglycemia in diabetic patients in Japan. The primary goal was to determine if nasal glucagon offered advantages over intramuscular glucagon. The data is structured using the FHIR (Fast Healthcare Interoperability Resources) standard and carries the identifier NCT03421379. It details the study's status and progress, reporting 'Completed,' along with specific timelines for various activities such as registration submission, results posting, and quality checks. This public data serves as a key example of utilizing FHIR platforms for standardized information sharing in medical research. It demonstrates how international clinical trial data can be structured and accessed, particularly in specialized areas like diabetes management in Japan. This highlights its value as foundational technology for seamlessly linking healthcare information across disparate systems. The target age group is 18 to 70 years, with Diabetes Mellitus being the primary condition of interest.
Technology Note
FHIR（Fast Healthcare Interoperability Resources）は医療データ交換の国際標準。このエントリの関連技術: FHIR
Original content copyright by respective publishers